Mereo Financial Statements From 2010 to 2026

MREO Stock

USD 0.42 0 0.48%

Mereo BioPharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Mereo BioPharma's valuation are provided below:

Gross Profit

367 K

Market Capitalization

68.8 M

Enterprise Value Revenue

43.4339

Revenue

500 K

Earnings Share

(0.25)

We have found one hundred twenty available fundamental ratios for Mereo BioPharma, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Mereo BioPharma's last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 4th of February 2026, Market Cap is likely to grow to about 489.3 M. Also, Enterprise Value is likely to grow to about 429.4 M

Mereo BioPharma Total Revenue

10 Million

Check Mereo BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mereo BioPharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 3.7 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 28.79, Dividend Yield of 0.0 or PTB Ratio of 8.02. Mereo financial statements analysis is a perfect complement when working with Mereo BioPharma Valuation or Volatility modules.

Build AI portfolio with Mereo Stock

Check out the analysis of Mereo BioPharma Correlation against competitors.

Mereo BioPharma Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

76 M

68.8 M

95.9 M

Slightly volatile

Short and Long Term Debt Total

7 M

7.4 M

11.4 M

Slightly volatile

Other Current Liabilities

7 M

5.1 M

5.9 M

Slightly volatile

Total Current Liabilities

16.3 M

15.9 M

11.4 M

Slightly volatile

Other Liabilities

339.8 K

357.6 K

4.5 M

Pretty Stable

Property Plant And Equipment Net

1.1 M

1.7 M

Pretty Stable

Accounts Payable

2.9 M

2.2 M

2.8 M

Slightly volatile

Cash

64.1 M

80.3 M

66.2 M

Pretty Stable

Non Current Assets Total

1.4 M

1.5 M

24.3 M

Slightly volatile

Cash And Short Term Investments

64.9 M

80.3 M

66.7 M

Pretty Stable

Net Receivables

3 M

2.9 M

2.6 M

Slightly volatile

Common Stock Total Equity

1.2 M

514.8 K

Slightly volatile

Liabilities And Stockholders Equity

76 M

68.8 M

95.9 M

Slightly volatile

Non Current Liabilities Total

1.7 M

1.8 M

13.5 M

Pretty Stable

Capital Surpluse

106.6 M

139.9 M

86.5 M

Slightly volatile

Other Current Assets

1.5 M

7.5 M

Very volatile

Other Stockholder Equity

651.6 M

620.6 M

236.8 M

Slightly volatile

Total Liabilities

16.8 M

17.7 M

24.8 M

Slightly volatile

Property Plant And Equipment Gross

3 M

2.2 M

2 M

Slightly volatile

Total Current Assets

73.6 M

86 M

72.6 M

Very volatile

Intangible Assets

549.8 K

578.7 K

24 M

Slightly volatile

Common Stock

3.7 M

3.5 M

1.2 M

Slightly volatile

Property Plant Equipment

2.5 M

2.1 M

1.6 M

Slightly volatile

Net Invested Capital

68.2 M

76.5 M

72 M

Slightly volatile

Net Working Capital

45.8 M

70.1 M

48.5 M

Very volatile

Capital Stock

3.7 M

3.5 M

1.2 M

Slightly volatile

Mereo BioPharma Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Interest Income

3.7 M

3.5 M

875.8 K

Slightly volatile

Selling General Administrative

18.2 M

30.4 M

14.9 M

Slightly volatile

Research Development

35.9 M

18.8 M

92.6 M

Slightly volatile

Total Operating Expenses

67 M

42.6 M

208.2 M

Slightly volatile

Depreciation And Amortization

987.6 K

1.3 M

618.6 K

Slightly volatile

Reconciled Depreciation

930.6 K

1.3 M

541.3 K

Slightly volatile

Mereo BioPharma Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation

909.6 K

1.3 M

616.9 K

Slightly volatile

Capital Expenditures

356.2 K

629.1 K

383.4 K

Pretty Stable

End Period Cash Flow

56.9 M

80.3 M

42.1 M

Slightly volatile

Stock Based Compensation

4.7 M

8.5 M

5.3 M

Pretty Stable

Begin Period Cash Flow

55.7 M

66 M

38.3 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Average Payables

6.2 M

4.3 M

5.9 M

Slightly volatile

Capex To Depreciation

0.7

0.74

4.0387

Very volatile

Cash Per Share

0.52

0.54

3.1129

Slightly volatile

Intangibles To Total Assets

0.0092

0.0097

0.2259

Slightly volatile

Current Ratio

9.25

6.21

14.3412

Slightly volatile

Capex Per Share

0.0052

0.0054

0.0117

Very volatile

Interest Debt Per Share

0.0576

0.0606

0.5605

Pretty Stable

Debt To Assets

0.14

0.0757

0.124

Slightly volatile

Graham Number

0.3

0.33

0.3612

Slightly volatile

Effective Tax Rate

0.0194

0.0204

0.1074

Slightly volatile

Long Term Debt To Capitalization

0.0684

0.072

0.8919

Pretty Stable

Total Debt To Capitalization

0.0816

0.0858

0.4763

Pretty Stable

Quick Ratio

11.13

6.21

15.4565

Slightly volatile

Net Income Per E B T

0.72

0.88

0.8714

Slightly volatile

Cash Ratio

8.39

5.8

13.6407

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

0.82

0.92

0.9976

Slightly volatile

Debt Ratio

0.14

0.0757

0.124

Slightly volatile

Gross Profit Margin

0.81

0.85

5.7761

Slightly volatile

Mereo BioPharma Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

489.3 M

466 M

173.3 M

Slightly volatile

Enterprise Value

429.4 M

408.9 M

128.6 M

Slightly volatile

Mereo Fundamental Market Drivers

Mereo Upcoming Events

	26th of March 2024 Upcoming Quarterly Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	26th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Mereo BioPharma Financial Statements

Mereo BioPharma investors utilize fundamental indicators, such as revenue or net income, to predict how Mereo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	7.4 M	4.4 M
Cost Of Revenue	979.6 K	930.6 K
Stock Based Compensation To Revenue	0.44	0.47
Sales General And Administrative To Revenue	1.66	1.74
Research And Ddevelopement To Revenue	1.57	1.65
Capex To Revenue	0.04	0.04
Revenue Per Share	0.07	0.07
Ebit Per Revenue	(3.27)	(3.10)

Pair Trading with Mereo BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mereo Stock

0.85	DWTX	Dogwood Therapeutics	Pair Corr
0.68	EDIT	Editas Medicine	Pair Corr

Moving against Mereo Stock

0.74	63E	ONWARD MEDICAL BV	Pair Corr
0.65	IMMP	Immutep Ltd ADR	Pair Corr
0.54	ENGN	enGene Holdings Common	Pair Corr
0.5	KYTX	Kyverna Therapeutics	Pair Corr
0.42	DSGN	Design Therapeutics	Pair Corr

The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.

The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:

How To Invest In Mereo

Details

Is Mereo Stock a good investment?

Details

What is Mereo BioPharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Mereo BioPharma Correlation against competitors.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Will Biotechnology sector continue expanding? Could Mereo diversify its offerings? Factors like these will boost the valuation of Mereo BioPharma. Expected growth trajectory for Mereo significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mereo BioPharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(0.25)

Revenue Per Share

0.003

Return On Assets

(0.40)

Return On Equity

(0.70)

Investors evaluate Mereo BioPharma Group using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mereo BioPharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mereo BioPharma's market price to deviate significantly from intrinsic value.

Understanding that Mereo BioPharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mereo BioPharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mereo BioPharma's market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Mereo Financial Statements From 2010 to 2026

Mereo BioPharma Total Revenue

10 Million

Mereo BioPharma Balance Sheet

Mereo BioPharma Income Statement

Mereo BioPharma Cash Flow Statement

Financial Ratios

Mereo BioPharma Valuation Data

Mereo Fundamental Market Drivers

Mereo Upcoming Events

About Mereo BioPharma Financial Statements

Pair Trading with Mereo BioPharma

Moving together with Mereo Stock

Moving against Mereo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY